1. Next-Generation Sequencing and ctDNA

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Molecular Testing Drives Lung Cancer Therapy

5. Workflow in Cancer Pathology Laboratory

6. Key Considerations in Cancer Pathology

7. Multidisciplinary Collaboration Is Critical More Information Leads to Better Results

8. Considerations for an Accurate Diagnosis

9. Right Treatment Requires Correct Diagnosis

10. Limitations of Biopsy

11. ctDNA Testing Multiple Assays Now Available

12. Validation of Rapid Plasma Genotyping in Advanced Lung Cancer

13. Role of ctDNA Testing Is Evolving

14. Which Lung Cancer Patients Are Candidates for ctDNA Testing?

15. Clinical Context Matters

16. Clinical Context Matters (cont)

17. Potential Future Directions in Plasma Genotyping

18. In Whom to Test ctDNA?

19. Send-Out vs In-House?

20. Selected ctDNA Assays

21. What Should Pathologists Know About ctDNA and NGS?

22. Plasma Genotyping Tradeoffs

23. Implications for Medical Oncologists

24. Key Takeaways

25. Abbreviations